Navigation Links
Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
Date:8/9/2013

NEW YORK, August 9, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), DaVita HealthCare Partners Inc. (NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), and VIVUS, Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Regeneron Pharmaceuticals Inc. Research Report

On August 6, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) reported its Q2 2013 financial results and provided an update on development programs. The Company's revenues increased 50.3% YoY to $457.6 million. Net income of $87.4 million or $0.79 per diluted share in Q2 2013, was higher as compared to net income of $76.7 million or $0.70 per diluted share in Q2 2012. Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, said, "We are pleased with the continued progress of EYLEA both in terms of commercialization and development in additional indications." He added, "Today, we reported positive Phase 3 data for EYLEA from the VIVID-DME and VISTA-DME trials in diabetic macular edema (DME). Based upon discussions with the U.S. Food & Drug Administration, we now plan to submit a regulatory application for approval for EYLEA in the DME indication in the U.S. later this year, approximately one year ahead of our previous plan." The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/REGN]

--

DaVita HealthCare Partners Inc. Research Report

On August 6, 2013, DaVita HealthCare Partners Inc. (DaVita) reported its Q2 2013 results. Total net revenues increased 50.1% YoY to $2.9 billion. Net income attributable to DaVita was $254.4 million or $2.37 per diluted share in Q2 2013, compared to $95.3 million or $0.99 per diluted share in Q2 2012. The Company also revised its consolidated operating income guidance for full-year 2013, and now expects it to be in the range of $1,830 million to $1,930 million, up from its previous guidance range of $1,800 million to $1,900 million. The Full Research Report on DaVita HealthCare Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/DVA]

--

Celldex Therapeutics, Inc. Research Report

On August 6, 2013, Celldex Therapeutics Inc. (Celldex) reported its Q2 2013 financial results and provided updates on its development programs. The Company's total revenue declined 95.2% YoY to c.$0.1 million. Net loss was $19 million or $0.24 per diluted share in Q2 2013, compared to a net loss of $13.8 million or $0.23 per diluted share in Q2 2012. Anthony Marucci, President and Chief Executive Officer of Celldex, said, "In the second quarter, Celldex continued to advance multiple clinical programs towards key inflection points. We completed several important steps in preparation for the initiation of our accelerated approval study of CDX-011 in triple negative breast cancer, including selecting a diagnostic partner. We also remain pleased with the pace of enrollment in our Phase 3 study of rindopepimut in frontline glioblastoma and look forward to presenting data from our Phase 2 study in refractory glioblastoma at the Society for Neuro-Oncology meeting later this year. In addition, we enrolled the first patient in our pilot study of CDX-1135 in dense deposit disease and initiated expansion cohorts in our Phase 1 study of CDX-1127 in metastatic melanoma and renal cell carcinoma." The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/CLDX]

--

ISIS Pharmaceuticals, Inc. Research Report

On August 6, 2013, ISIS Pharmaceuticals, Inc. (Isis) reported its Q2 2013 financial results. The Company's total revenue decreased 19.5% YoY to $38 million. Net loss was $10.1 million or $0.09 per diluted share in Q2 2013, compared to a net loss of $1.2 million or $0.01 per diluted share in Q2 2012. B. Lynne Parshall, Chief Operating Officer of Isis, said, "We ended the quarter with a significantly improved financial position. We added a new partner, Roche, for one of our severe and rare disease programs. We advanced our broad pipeline of drugs, and we reported positive Phase 2 data from our drug, ISIS-APOCIIIRx. These data support our belief that antisense drugs can be safe and effective treatments for many different diseases. All of these activities have significantly contributed to our financial performance this year and the increase in value of our technology and our drugs in development."The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/ISIS]

--

VIVUS, Inc. Research Report

On August 6, 2013, VIVUS, Inc. (VIVUS) reported its Q2 2013 financial results.Net product revenue from sales of Qsymia, the first FDA-approved once daily combination therapy for the treatment of obesity, was $5.5 million in Q2 2013. The Company reported net loss of $55.5 million or $0.55 per diluted share, compared to a net loss of $24 million or $0.24 per diluted share in Q2 2012. VIVUS said that the increased net loss in Q2 2013 as compared to Q2 2012 is primarily attributable to increased selling, general and administrative expenses related to commercialization activities for Qsymia. The Full Research Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/VVUS]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.



'/>"/>
SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Financial Results, Earnings Schedules, Quarterly Dividends, and Top Rankings - Research Report on Quest Diagnostics, PerkinElmer, PAREXEL, Covance, and ICON
2. Innophos Holdings, Inc. Declares Quarterly Dividend
3. CVS Caremark Corporation Announces Quarterly Dividend
4. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
5. AbbVie Declares Quarterly Dividend
6. Zimmer Announces Quarterly Dividend for Second Quarter of 2013
7. Correction Notice Of Press Release On Quarterly Dividend Announcement
8. Sigma-Aldrich Corporation Declares $0.215 Per Share Quarterly Dividend
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
10. Par Pharmaceutical Announces Quarterly Conference Call
11. UPDATE: Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):